📰 Nsclc News
Page 47 - Nsclc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nsclc. Real-time updates on events, politics, business and more.
August 26, 2022
Two new meta-analyses find that immune checkpoint inhibitors improve survival by about 10% compared with chemotherapy and do not diminish quality of life.
August 17, 2022
Screening for lung cancer starts at 55 years, and has led to earlier diagnosis of disease in older patients; but younger adults are still being diagnosed with late stage disease.
August 15, 2022
NanoString Technologies Inc. reviews the data and demonstrates of the CosMx™ Spatial Molecular Imager
August 12, 2022
LONDON (dpa-AFX) - Daiichi Sankyo and AstraZeneca's (AZN, AZN.L) Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or
August 12, 2022
Specific enrichments are associated with oral mucositis and recurrence after radiation therapy.
August 12, 2022
The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non–small cell lung cancer whose tumors have HER2 mutations.
August 10, 2022
A new immunotherapy from China may offer another option for post-chemoradiotherapy treatment in patients with unresectable with stage III non-small cell lung cancer.
August 10, 2022
Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.
August 8, 2022
GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator Professor Yi-Long Wu was invited to highlight key data
August 5, 2022
SHANGHAI, Aug. 5, 2022 /PRNewswire/ -- Dizal presented positive clinical updates highlighting the therapeutic potential of sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal